Pharmacy Practice

Medicine & Life Sciences

1. Pharmacokinetics 100%
2. HIV 83%
3. Pharmacists 69%
4. Pharmacies 49%
5. Pharmacy 45%
6. efavirenz 41%
7. Therapeutics 40%
8. Pharmaceutical Preparations 39%
9. Venous Thromboembolism 38%
10. Tenofovir 37%
11. Anticoagulants 29%
12. Ritonavir 27%
13. Nevirapine 25%
14. Safety 25%
15. Critical Illness 24%
16. HIV-1 24%
17. Guidelines 22%
18. Point-of-Care Testing 21%
19. rifapentine 20%
20. Students 20%
21. Raltegravir Potassium 19%
22. Atazanavir Sulfate 19%
23. Lopinavir 19%
24. Intensive Care Units 18%
25. Anti-Bacterial Agents 18%
26. Drug Interactions 18%
27. Vancomycin 17%
28. Population 17%
29. Proton Pump Inhibitors 17%
30. Pharmacogenetics 16%
31. Costs and Cost Analysis 16%
32. Kidney 16%
33. Tuberculosis 15%
34. Lymphoid Tissue 15%
35. Pharmacy Schools 15%
36. Isoniazid 14%
37. Clopidogrel 14%
38. Omeprazole 14%
39. Contraceptive Agents 14%
40. Pre-Exposure Prophylaxis 13%
41. Medication Errors 13%
42. Physicians 13%
43. Pediatrics 13%
44. Medulloblastoma 13%
45. Pharmacy Education 13%
46. Pharmacy Students 13%
47. Lansoprazole 13%
48. GS-7340 13%
49. Acute Coronary Syndrome 13%
50. Emtricitabine 12%
51. VSW1198 12%
52. Critical Care 12%
53. Levonorgestrel 12%
54. etravirine 12%
55. Neoplasms 12%
56. Economics 12%
57. Pharyngitis 11%
58. Child 11%
59. HIV Infections 11%
60. Education 11%
61. Infections 11%
62. Virus Diseases 11%
63. Rifabutin 11%
64. etonogestrel 11%
65. Drug Therapy 10%
66. Practice Guidelines 10%
67. Prescriptions 10%
68. Point-of-Care Systems 10%
69. Coronavirus 10%
70. Pneumococcal Pneumonia 10%
71. Formularies 10%
72. Zinc 10%
73. Reverse Transcriptase Inhibitors 10%
74. trovafloxacin 9%
75. Azithromycin 9%
76. Hemorrhage 9%
77. Cyclosporine 9%
78. Cytokines 9%
79. Breast Neoplasms 9%
80. Communicable Diseases 9%
81. Blood Cells 9%
82. Integrases 9%
83. Electronic Health Records 9%
84. Hydroxymethylglutaryl-CoA Reductase Inhibitors 9%
85. dolutegravir 9%
86. Clinical Trials 9%
87. Farnesyltranstransferase 9%
88. Multiple Myeloma 9%
89. Inflammation 9%
90. Darunavir 8%
91. Healthy Volunteers 8%
92. Rilpivirine 8%
93. Severe Acute Respiratory Syndrome 8%
94. Medication Therapy Management 8%
95. Percutaneous Coronary Intervention 8%
96. Patient Care 8%
97. Tablets 8%
98. In Vitro Techniques 8%
99. Curriculum 8%
100. Cytochrome P-450 CYP2B6 8%